Daratumumab for acquired immune thrombotic thrombocytopenic purpura

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, collaborative effort to collect real-world data on daratumumab use in patients with acquired immune TTP who are refractory or intolerant to standard immunosuppression. Investigators will gather clinical and laboratory outcomes, including safety data, from multiple centers and report the proportion of patients achieving ADAMTS13 activity above 20% at six months after first daratumumab administration. The protocol includes adults with confirmed immune TTP (ADAMTS13 activity less than 10% with anti-ADAMTS13 antibodies) who have been treated with daratumumab and have at least six months of follow-up. Existing evidence is limited to case reports, so this larger collection aims to clarify efficacy and tolerability in a broader group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity \<10% with anti-ADAMTS13 antibodies detected);
* aged ≥ 18 years;
* male and female patients;
* treated with daratumumab for iTTP.

Exclusion Criteria:

* patients unwilling or unable to provide their informed consent;
* follow-up \< 6 months after daratumumab administration.

Where it's running

• Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Juri A Giannotta, M.D.
• Email: juri.giannotta@policlinico.mi.it
• Phone: +390255035273

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fewer-doses daratumumab added to VRd for newly diagnosed multiple myeloma

  This study tests whether a less-frequent daratumumab dosing plan added to VRd can help patients with newly diagnosed multiple myeloma achieve more MRD negativity.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07891923

• BCD-248 plus daratumumab in relapsed or refractory multiple myeloma

  This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.

  Recruiting at 16 sites Phase 3 Biocad · Homyel and 15 other locations · NCT07742215

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• A combination therapy for teens and young adults with relapsed or refractory T-ALL/T-LBL

  This phase 1 study tests a four-drug regimen (venetoclax, dexamethasone, bortezomib, and daratumumab) in adolescents and young adults whose T-cell ALL or T-cell lymphoblastic lymphoma has come back or not responded.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07513129

• Maintaining myeloma with less frequent daratumumab plus lenalidomide

  This phase 2 study tests a reduced-dosing schedule of daratumumab with lenalidomide to maintain remission in adults with multiple myeloma after stem cell transplant.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07485647

• GR1803 injection versus daratumumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

  This trial tests whether GR1803 injection works better than daratumumab combined with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma who have had one to three prior treatments.

  Recruiting Phase 3 Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Tianjin · NCT07452198

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.